What is Medical Marijuana?
Medical marijuana is the consumable marijuana product developed from a strain (or variety of strains) of the cannabis plant (sativa, indica, or hybrid) which is bred and extracted for desired levels of THC, CBD and Terpenes which best address the symptoms of specific medical conditions. (Learn about cannabis terminology here.)
Research scientists, under watchful FDA and DEA authority, are beginning to do research on human subjects (double blind studies where there is a control group and a treatment group with the same medical condition, and where neither the researcher nor the participant knows whether the participant is receiving active substance or a placebo) to prove if an active cannabis substance has an effect on the treatment group that is significantly different from controls.
The FDA has approved three synthetic medicines mimicking the cannabinoid dronabinol, for use in anorectics and AIDS patients for dietary stimulation, and in chemotherapy patients for nausea. They go under the brand names: Marinol, Syndros, and Cesamet. Additionally, as of June 25, 2018, after numerous double blind clinical trials, the FDA approved the first drug made directly from the cannabis plant called Epidiolex by GW Pharma. The product is approved for rare and severe conditions of epilepsy.
Animal studies are also being conducted on uses for cannabis. One example published by the American Association for Cancer Research by KA Scott, et al in London has shown that in cases of aggressive brain cancer, tumor size reduction in mice is greater in cells that are pre-treated with both THC and CBD prior to radiation. Of course, human trials will come much later with various phases of clinical study.
Cannatrials’ Mission and Vision is to create partnerships at the State level where cannabis already is legal, with medical marijuana products formulated by producers and growers, and distributed by dispensaries.
CannaTrials will bring together marijuana doctors and patients with ailments to perform comparative clinical trials which determine whether specific products effectively improve medical conditions so that product labeling is accurate, has medical science behind it, which increases consumer trust and reliance on products, and increases the reputation of both producers and dispensaries participating in studies.
This path will quicken the acceptance and use of medical marijuana for clinical purposes by patients, physicians, processors and growers, dispensaries and state governments.